1156-P: Depression in Adolescents with Type 2 Diabetes (T2D) Attending a Multidisciplinary Tertiary Care (MTC) Clinic

T2D incidence has risen ~5% per year in adolescents over the past decade. Comorbidities are common, requiring MTC that addresses medication management and lifestyle change. Clinical guidelines recommend depression monitoring, but depression in relation to health indices (e.g., HbA1c, lipids) in adolescents with T2D attending MTC is not well characterized. We aimed to evaluate depression and in-clinic psychology contact (PC) as it relates to health indices in youth with T2D presenting to MTC. Retrospective chart review of youths 12-18y with T2D was conducted for MTC visits at a pediatric hospital from 2016-21. Depression was assessed with the 20-item Center for Epidemiologic Studies-Depression Scale (CES-D). PCs were determined by charted encounters. Health indices were extracted from initial clinic visit. Fisher’s exact/Kruskal Wallis tests assessed associations of depression with PC and patient health indices. N=126 adolescents (M age±SD 15±2y) with T2D (onset age 13±3y). Majority (73%) were screened for depression in the first 2 MTC visits. Of those, 48% reported at least mildly elevated symptoms (CES-D=16); 27% had moderately elevated symptoms (CES-D=20). 93% (n=117) of all patients saw a clinic psychologist in the first 2 MTC visits; PC was more likely for youths with CES-D=16 (X2=6.97, p.01). Youths with CES-D=20 had higher total cholesterol (212±45 vs 176±47mg/dL, p.01) and LDL (131±43 vs 90±34 mg/dL, p.01) than those with no-to-mild symptoms. HbA1c (9±3%) and triglycerides (253±191 mg/dL) were elevated in all patients, regardless of depression. Overall, depression screening with prompt PC is feasible in MTC for adolescents with T2D. Nearly half of youth screened had elevated depression, and youth with moderate symptoms demonstrated elevated LDL and cholesterol levels. Future work is needed to delineate the progression of depression with comorbidities, and to evaluate if early psychology contact increases likelihood of positive health outcomes. Disclosure S.G. Talachutla: None. H. Gawey: None. A. Gutierrez-Colina: None. S.E.D. Perzow: None. M.M. Kelsey: Other Relationship; Rhythm Pharmaceuticals, Inc., Lilly Diabetes. L.B. Shomaker: None.